Cardiac Fibroblast Differentiation via Chemically Defined Medium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for efficient and cost-effective protocols to generate functional cardiac fibroblasts under chemically defined culture conditions, as existing methods are limited by the scarcity of primary human cardiac fibroblasts and their short lifespan, making it challenging for cardiovascular research and therapeutic applications.
Innovation Solution
A method involving the culture of human cardiac mesoderm progenitor cells in a chemically defined medium with fibroblast growth factor, such as bFGF/FGF2, to obtain cardiac fibroblasts that are capable of long-term maintenance and expression of specific markers like GATA4 and HAND2, without the need for cell separation or selection, and can be used to create a human arrhythmia model or screen therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary human cardiac fibroblasts are used, then functional cardiac fibroblasts are obtained, but their scarcity and short lifespan limit research and therapeutic applications
Solution Approach 1:
The patent creates copies of primary human cardiac fibroblasts by differentiating human pluripotent stem cells into cardiac fibroblasts through chemically defined culture conditions. This produces unlimited supplies of functional cardiac fibroblasts that replicate the properties of primary cells without the limitations of scarcity and short lifespan
Solution Approach 2:
The patent performs preliminary differentiation of human pluripotent stem cells into cardiac fibroblasts before they are needed for experiments or therapies. The chemically defined culture conditions pre-establish the functional characteristics of cardiac fibroblasts, ensuring they are ready for use without the need for primary cell isolation at the time of application
2Ease of manufacture
If chemically defined culture conditions are used, then cost-effectiveness and scalability are improved, but existing methods lack efficiency in generating functional cardiac fibroblasts
Solution Approach 1:
The patent optimizes culture parameters including specific growth factors (bFGF, FGF2), serum-free conditions, and defined media compositions to achieve both high efficiency in generating functional cardiac fibroblasts and cost-effectiveness. The chemically defined conditions eliminate the need for expensive serum while maintaining high differentiation efficiency
Solution Approach 2:
The patent establishes continuous culture conditions that maintain cardiac fibroblast functionality throughout the differentiation and expansion process. The chemically defined media supports continuous proliferation and functional maintenance without requiring passage to different media types or supplementation with undefined components
Data Source
AI summary
Methods for generating high-yield high-purity cardiac fibroblasts are described. Differentiation methods comprising thematically defined culture conditions and methods for in vitro maintenance of human pluripotent stern cell-derived cardiac fibroblasts are also provided.